Bavarian Nordic's Covid-19 vaccine has difficult journey ahead

An analyst and a professor in vaccine design think the Danish drugmaker might have arrived late to the Covid-19 vaccine party, as CEO Paul Chaplin also lowers his ambitions.

Photo: Bavarian Nordic / PR

Analyst at Pharmium Securities Frédéric Gomez and Camilla Foged, professor in vaccine design at Copenhagen University, are skeptical about Bavarian Nordic’s plan to conquer part of the huge Covid-19 market, reports Danish media Finans.

”Bavarian is in a changing race, and that is the challenge. I’m not so sure that there is a definite need for the company’s vaccine in the current environment,” Gomez writes in an email to the media, pointing out that should Bavarian even make it to approval, it would be a late entry to a market where competitors are already providing well-functioning technologies.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs